Ontology highlight
ABSTRACT:
SUBMITTER: Schindeler A
PROVIDER: S-EPMC7271822 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Schindeler Aaron A Biggin Andrew A Munns Craig F CF
Frontiers in endocrinology 20200528
Burosumab (KRN23) is an FGF23 neutralizing antibody that has been the subject of several recent clinical trials principally focused on the treatment of hypophosphatemic rickets in patients with X-linked hypophosphatemia (XLH). Since the first publications in 2014, these trials have demonstrated efficacy with minimal safety concerns in both adult and pediatric cohorts. These studies have used dose-escalation to establish a dosing regimen that is well-tolerated in clinical use. This review summari ...[more]